887471-39-8

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-3-hydroxy-2-nitropyridine is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 6-Chloro-3-hydroxy-2-nitropyridine is utilized as an intermediate in the production of agrochemicals. Its properties make it suitable for the creation of compounds that can be used in pest control and crop protection, thereby supporting agricultural productivity.
Used in Organic Chemistry Research:
6-Chloro-3-hydroxy-2-nitropyridine also serves as a building block in organic chemistry, used by researchers to create more complex organic compounds. Its versatility in forming various chemical structures makes it valuable for scientific exploration and the development of novel organic materials.

Upstream product

• 41288-96-4 6-chloropyridine-3-ol 

Downstream Products

• 159309-66-7 2-amino-6-chloropyridin-3-ol 
• 1355026-37-7 C₁₃H₉Cl₃N₂O₄ 
• 887471-40-1 3-benzyloxy-6-chloro-2-nitro-pyridine 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL)

The application relates to heterocyclic compounds of the general formula (I), compositions comprising such compounds, a process for preparing these compounds and their medical use. The compounds act as monoacylglycerol lipase (MAGL) inhibitors and are useful in the treatment of neuroinflammation, neurodegenerative diseases, pain, cancer or mental disorders.

Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies

Small molecule potent IRAK4 inhibitors from a novel bicyclic heterocycle class were designed and synthesized based on hits identified from Aurigene's compound library. The advanced lead compound, CA-4948, demonstrated good cellular activity in ABC DLBCL and AML cell lines. Inhibition of TLR signaling leading to decreased IL-6 levels was also observed in whole blood assays. CA-4948 demonstrated moderate to high selectivity in a panel of 329 kinases as well as exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation. CA-4948 was well tolerated in toxicity studies in both mouse and dog at efficacious exposure. The overall profile of CA-4948 prompted us to select it as a clinical candidate for evaluation in patients with relapsed or refractory hematologic malignancies including non-Hodgkin lymphoma and acute myeloid leukemia.

SUBSTITUTED AZA COMPOUNDS AS IRAK-4 INHIBITORS

The present invention provides substituted aza compounds of formula (I) or (II) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK-4 and/or for the treatment of diseases or disorders induced by IRAK-4.

BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY

A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune

AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS

The present invention relates to α7 nicotinic receptor agonists of formula (I) as described herein and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mamma